LIVIN和HLA-I类分子在肾透明细胞癌中的表达及其临床意义  

Expression and Clinical Significance of LIVIN and HLA-I in the Clear Cell Renal cell Carcinomas

作　　者：谭钧文[1] 原劲杨[1] 王涌泉[1] 安瑞华[1] 林洋[1] 

机构地区：[1]哈尔滨医科大学附属第一医院泌尿外科,黑龙江哈尔滨150001

出　　处：《现代生物医学进展》2014年第25期4883-4886,4931,共5页Progress in Modern Biomedicine

摘　　要：目的:探讨凋亡抑制蛋白Livin与人类白细胞抗原(HLA)I类分子在人类肾脏透明细胞癌(clear cell renal cell carcinoma,ccRCC)中的表达及其临床意义。方法:选择哈尔滨医科大学附属第一医院2007年12月至2011年12月收治的拟行肾癌根治术的患者80例,应用免疫组织化学方法检测80例ccRCC组织与10例癌旁正常肾组织中Livin及HLA-I类分子的表达,并分析其与患者临床病理特征之间的关系。结果:10例癌旁正常肾组织中均未见Livin的阳性表达,而HLA-I类分子的阳性表达率为100%。ccRCC组织中,Livin的阳性表达率及HLA I类分子表达下调百分率分别为41(51.25%)例和48(60.00%)例,Livin的阳性表达率与正常组相比差异有统计学差异(P<0.05)。ccRCC组织中Livin的阳性表达率与淋巴结转移、组织分化程度显著相关(P<0.05),而HLA I类分子的表达下调百分率与患者的性别、年龄、肿瘤分级、淋巴结转移及分期均无相关性(P>0.05)。ccRCC组织中Livin的表达与HLA I类分子的表达亦无显著相关性(P>0.05)。结论:Livin、HLA I类分子表达异常参与了ccRCC的发生、发展过程,Livin可能成为ccRCC的一个重要预后指标和治疗靶点。Objective： To study the expression and clinical significance of Livin and HLA-I in clear cell renal cell carcinoma（ccRCC）. Methods： 80 patients who underwent radical nephrectomy from December 2007 to December 2011 in the First Affiliated Hospital of Harbin Medical University were selected. Immunohistochemical staining was used to determine the expression of Livin and HLA-I in 80 cases ofccRCC tissues and 10 cases of normal renal tissues, and analyze its relationship with clinicopathological features of patients. Results： The positive rate of Livin was 0 % while HLA-I was expressed in all normal renal tissues. Livin was expressed in 41 （51.25 %） of 80 renal cancer tissues, and the expression of HLA-I was down-regulated in 48 （60.00 %）specimens. The expression of Livin in ccRCC was associated with the metastasis and the degree of tissue differentiation, but the expression of HLA-I had no correlation with age, sex, TNM stage or Lymphatic metastasis. The expression of Livin was not correlated with that of HLA-I in ccRCC. Conclusion： Livin and HLA-I may play an important role in the occurrence and progression of ccRCC, Livin may be important diagnostic / therapeutic indicator or target in ccRCC.

关 键 词：LIVIN HLAI类分子 肾透明细胞癌 免疫组织化学 免疫治疗 

分 类 号：R737.11[医药卫生—肿瘤]